SCHEMBL6484518

SCHEMBL6484518

CCCOc1ccc(S(=O)(=O)N2CCN(CCF)CC2)cc1-c1nc2c(CCC)cn(C)c2c(=O)[nH]1

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6641001 0.99 PDE5A (0.79) PDE5A
SCHEMBL6645452 0.97 PDE5A (0.75) PDE5A
SCHEMBL6486240 0.96 PDE5A (0.82) PDE5A
Hydrochloric Acid SCHEMBL6644508 0.95 PDE5A (0.81) PDE5A
SCHEMBL6645256 0.95 PDE5A (0.81) PDE5A
SCHEMBL6641871 0.95 PDE5A (0.80) PDE5A
Hydrochloric Acid SCHEMBL6645051 0.94 PDE5A (0.79) PDE5A
SCHEMBL6643287 0.93 PDE5A (0.78) PDE5A
SCHEMBL6483207 0.93 PDE5A (0.88) PDE5A
SCHEMBL6641469 0.92 PDE5A (0.76) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271916-B2 Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (KR) 2016-03-01 US claimed
US-20140187775-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2014-07-03 US claimed
WO-2013036081-A2 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2013-03-14 WO claimed
US-6962911-B2 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2005-11-08 US claimed
EP-1257553-B1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO LTD (KR) 2004-05-26 EP claimed
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2003-09-11 US claimed
US-9271916-B2 Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (KR) 2016-03-01 US disclosed
US-20140187775-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2014-07-03 US disclosed
WO-2013036081-A2 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2013-03-14 WO disclosed
EP-1257553-B1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO LTD (KR) 2004-05-26 EP disclosed
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use CYP2C19, DHPS, SDHA PDE5A 686/4885
US-20140187775-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR PDE5A, PDE3B, PDE3A PDE5A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.